Elle peut être asymptomatique ou provoquer fatigue, douleurs articulaires, jaunisse.
Hépatite BSymptômesJaunisse
#3
Quels symptômes sont associés à l'hépatite C ?
Fatigue, douleurs abdominales, jaunisse, mais souvent asymptomatique.
Hépatite CSymptômesAsymptomatique
#4
Les symptômes de l'hépatite D sont-ils similaires ?
Oui, ils ressemblent à ceux de l'hépatite B, avec des complications possibles.
Hépatite DSymptômesComplications
#5
Quels signes indiquent une hépatite E ?
Fièvre, fatigue, nausées, et jaunisse, surtout dans les zones à risque.
Hépatite ESymptômesZones à risque
Prévention
5
#1
Comment prévenir l'hépatite A ?
Vaccination, hygiène alimentaire, et lavage des mains sont essentiels.
PréventionHépatite AVaccination
#2
Quelles mesures pour l'hépatite B ?
Vaccination, éviter le partage d'aiguilles et rapports protégés.
Hépatite BPréventionVaccination
#3
L'hépatite C peut-elle être évitée ?
Éviter le partage d'aiguilles et pratiquer des rapports protégés aide à prévenir.
Hépatite CPréventionRapports protégés
#4
Y a-t-il un vaccin pour l'hépatite E ?
Actuellement, il n'existe pas de vaccin commercialisé pour l'hépatite E.
Hépatite EVaccinPrévention
#5
Comment réduire le risque d'hépatite D ?
Prévenir l'hépatite B par vaccination réduit le risque d'hépatite D.
Hépatite DPréventionVaccination
Traitements
5
#1
Comment traite-t-on l'hépatite A ?
Il n'y a pas de traitement spécifique, repos et hydratation sont recommandés.
Hépatite ATraitementHydratation
#2
Quels traitements existent pour l'hépatite B ?
Antiviraux comme la lamivudine ou l'interféron peuvent être prescrits.
Hépatite BAntivirauxInterféron
#3
L'hépatite C peut-elle être guérie ?
Oui, avec des antiviraux à action directe, la guérison est possible.
Hépatite CAntivirauxGuérison
#4
Y a-t-il un vaccin pour l'hépatite B ?
Oui, un vaccin efficace est disponible pour prévenir l'hépatite B.
VaccinHépatite BPrévention
#5
Comment gérer l'hépatite D ?
Le traitement de l'hépatite B est essentiel, car l'hépatite D dépend de celle-ci.
Hépatite DHépatite BTraitement
Complications
5
#1
Quelles complications peuvent survenir avec l'hépatite B ?
Cirrhose, cancer du foie, et insuffisance hépatique sont des complications possibles.
Hépatite BCirrhoseCancer du foie
#2
L'hépatite C peut-elle causer des complications ?
Oui, elle peut mener à la cirrhose et au cancer du foie sur le long terme.
Hépatite CCirrhoseCancer du foie
#3
Quelles sont les complications de l'hépatite D ?
Elle peut aggraver l'hépatite B, entraînant des complications hépatiques sévères.
Hépatite DHépatite BComplications hépatiques
#4
L'hépatite A entraîne-t-elle des complications ?
Rarement, mais des cas graves peuvent survenir, surtout chez les personnes âgées.
Hépatite AComplicationsPersonnes âgées
#5
Quelles complications sont liées à l'hépatite E ?
Peuvent inclure des cas graves chez les femmes enceintes, comme l'insuffisance hépatique.
Hépatite EComplicationsFemmes enceintes
Facteurs de risque
5
#1
Quels sont les facteurs de risque pour l'hépatite A ?
Voyages dans des zones à risque, consommation d'eau contaminée, et aliments crus.
Hépatite AFacteurs de risqueContamination
#2
Quels comportements augmentent le risque d'hépatite B ?
Partage d'aiguilles, rapports non protégés, et transfusions sanguines non testées.
Hépatite BFacteurs de risqueTransfusions sanguines
#3
Qui est à risque pour l'hépatite C ?
Les consommateurs de drogues injectables et les personnes ayant des rapports à risque.
Hépatite CFacteurs de risqueDrogues injectables
#4
Les travailleurs de la santé sont-ils à risque d'hépatite ?
Oui, ils sont exposés à des fluides corporels et doivent suivre des protocoles de sécurité.
HépatiteTravailleurs de la santéSécurité
#5
Les personnes vivant avec le VIH sont-elles à risque d'hépatite ?
Oui, elles ont un risque accru d'infections par les virus de l'hépatite.
VIHHépatiteFacteurs de risque
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Anticorps de l'hépatite : Questions médicales les plus fréquentes",
"headline": "Anticorps de l'hépatite : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Anticorps de l'hépatite : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-27",
"dateModified": "2025-04-22",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Anticorps de l'hépatite"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Anticorps antiviraux",
"url": "https://questionsmedicales.fr/mesh/D000914",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps antiviraux",
"code": {
"@type": "MedicalCode",
"code": "D000914",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.254"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Anticorps de l'hépatite A",
"alternateName": "Hepatitis A Antibodies",
"url": "https://questionsmedicales.fr/mesh/D035922",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps de l'hépatite A",
"code": {
"@type": "MedicalCode",
"code": "D035922",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.254.450.251"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Anticorps de l'hépatite B",
"alternateName": "Hepatitis B Antibodies",
"url": "https://questionsmedicales.fr/mesh/D006510",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps de l'hépatite B",
"code": {
"@type": "MedicalCode",
"code": "D006510",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.254.450.504"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Anticorps de l'hépatite C",
"alternateName": "Hepatitis C Antibodies",
"url": "https://questionsmedicales.fr/mesh/D018937",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps de l'hépatite C",
"code": {
"@type": "MedicalCode",
"code": "D018937",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.254.450.510"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Anticorps de l'hépatite",
"alternateName": "Hepatitis Antibodies",
"code": {
"@type": "MedicalCode",
"code": "D006508",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Mansun Law",
"url": "https://questionsmedicales.fr/author/Mansun%20Law",
"affiliation": {
"@type": "Organization",
"name": "Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California 92109, USA."
}
},
{
"@type": "Person",
"name": "Michiko Koga",
"url": "https://questionsmedicales.fr/author/Michiko%20Koga",
"affiliation": {
"@type": "Organization",
"name": "Division of Infectious Diseases, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan."
}
},
{
"@type": "Person",
"name": "Makoto Saito",
"url": "https://questionsmedicales.fr/author/Makoto%20Saito",
"affiliation": {
"@type": "Organization",
"name": "Division of Infectious Diseases, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan."
}
},
{
"@type": "Person",
"name": "Eisuke Adachi",
"url": "https://questionsmedicales.fr/author/Eisuke%20Adachi",
"affiliation": {
"@type": "Organization",
"name": "Department of Infectious Diseases and Applied Immunology, Hospital of the Institute of Medical Science, The University of Tokyo, Tokyo, Japan."
}
},
{
"@type": "Person",
"name": "Amato Otani",
"url": "https://questionsmedicales.fr/author/Amato%20Otani",
"affiliation": {
"@type": "Organization",
"name": "Department of Infectious Diseases and Applied Immunology, Hospital of the Institute of Medical Science, The University of Tokyo, Tokyo, Japan."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Making clear and effective communication SOuND BETTeR for patients with communication barriers.",
"datePublished": "2023-10-16",
"url": "https://questionsmedicales.fr/article/37844910",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/1742-6723.14323"
}
},
{
"@type": "ScholarlyArticle",
"name": "Perceived Communication Barriers by Caregivers of Psychiatric Patients.",
"datePublished": "2023-07-20",
"url": "https://questionsmedicales.fr/article/37489673",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.33314/jnhrc.v20i4.4249"
}
},
{
"@type": "ScholarlyArticle",
"name": "Communication sheet eases barriers for Japanese patients and health professionals.",
"datePublished": "2022-07-30",
"url": "https://questionsmedicales.fr/article/35907847",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12913-022-08371-x"
}
},
{
"@type": "ScholarlyArticle",
"name": "Can ChatGPT rescue or assist with language barriers in healthcare communication?",
"datePublished": "2023-08-14",
"url": "https://questionsmedicales.fr/article/37591023",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.pec.2023.107940"
}
},
{
"@type": "ScholarlyArticle",
"name": "Caring for older culturally and linguistically diverse patients with Cancer: Healthcare Providers' perceived barriers to communication.",
"datePublished": "2022-05-17",
"url": "https://questionsmedicales.fr/article/35589543",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jgo.2022.04.009"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Globulines",
"item": "https://questionsmedicales.fr/mesh/D005916"
},
{
"@type": "ListItem",
"position": 5,
"name": "Sérum-globulines",
"item": "https://questionsmedicales.fr/mesh/D012712"
},
{
"@type": "ListItem",
"position": 6,
"name": "Immunoglobulines",
"item": "https://questionsmedicales.fr/mesh/D007136"
},
{
"@type": "ListItem",
"position": 7,
"name": "Anticorps",
"item": "https://questionsmedicales.fr/mesh/D000906"
},
{
"@type": "ListItem",
"position": 8,
"name": "Anticorps antiviraux",
"item": "https://questionsmedicales.fr/mesh/D000914"
},
{
"@type": "ListItem",
"position": 9,
"name": "Anticorps de l'hépatite",
"item": "https://questionsmedicales.fr/mesh/D006508"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Anticorps de l'hépatite - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Anticorps de l'hépatite",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Anticorps de l'hépatite",
"description": "Comment détecte-t-on les anticorps de l'hépatite ?\nQuels types d'anticorps sont testés ?\nQuand faut-il faire un test d'anticorps ?\nLes anticorps indiquent-ils une infection active ?\nPeut-on avoir des anticorps sans symptômes ?",
"url": "https://questionsmedicales.fr/mesh/D006508?mesh_terms=Communication+Barriers#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Anticorps de l'hépatite",
"description": "Quels sont les symptômes de l'hépatite A ?\nL'hépatite B présente-t-elle des symptômes ?\nQuels symptômes sont associés à l'hépatite C ?\nLes symptômes de l'hépatite D sont-ils similaires ?\nQuels signes indiquent une hépatite E ?",
"url": "https://questionsmedicales.fr/mesh/D006508?mesh_terms=Communication+Barriers#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Anticorps de l'hépatite",
"description": "Comment prévenir l'hépatite A ?\nQuelles mesures pour l'hépatite B ?\nL'hépatite C peut-elle être évitée ?\nY a-t-il un vaccin pour l'hépatite E ?\nComment réduire le risque d'hépatite D ?",
"url": "https://questionsmedicales.fr/mesh/D006508?mesh_terms=Communication+Barriers#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Anticorps de l'hépatite",
"description": "Comment traite-t-on l'hépatite A ?\nQuels traitements existent pour l'hépatite B ?\nL'hépatite C peut-elle être guérie ?\nY a-t-il un vaccin pour l'hépatite B ?\nComment gérer l'hépatite D ?",
"url": "https://questionsmedicales.fr/mesh/D006508?mesh_terms=Communication+Barriers#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Anticorps de l'hépatite",
"description": "Quelles complications peuvent survenir avec l'hépatite B ?\nL'hépatite C peut-elle causer des complications ?\nQuelles sont les complications de l'hépatite D ?\nL'hépatite A entraîne-t-elle des complications ?\nQuelles complications sont liées à l'hépatite E ?",
"url": "https://questionsmedicales.fr/mesh/D006508?mesh_terms=Communication+Barriers#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Anticorps de l'hépatite",
"description": "Quels sont les facteurs de risque pour l'hépatite A ?\nQuels comportements augmentent le risque d'hépatite B ?\nQui est à risque pour l'hépatite C ?\nLes travailleurs de la santé sont-ils à risque d'hépatite ?\nLes personnes vivant avec le VIH sont-elles à risque d'hépatite ?",
"url": "https://questionsmedicales.fr/mesh/D006508?mesh_terms=Communication+Barriers#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment détecte-t-on les anticorps de l'hépatite ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Par des tests sanguins spécifiques qui mesurent les anticorps présents."
}
},
{
"@type": "Question",
"name": "Quels types d'anticorps sont testés ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les anticorps anti-HAV, anti-HBV, anti-HCV, anti-HEV, et anti-HDV."
}
},
{
"@type": "Question",
"name": "Quand faut-il faire un test d'anticorps ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Après une exposition suspectée ou en cas de symptômes d'hépatite."
}
},
{
"@type": "Question",
"name": "Les anticorps indiquent-ils une infection active ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Pas toujours, certains anticorps indiquent une infection passée ou une immunité."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des anticorps sans symptômes ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines personnes peuvent être asymptomatiques tout en ayant des anticorps."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes de l'hépatite A ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fièvre, fatigue, nausées, douleurs abdominales, jaunisse."
}
},
{
"@type": "Question",
"name": "L'hépatite B présente-t-elle des symptômes ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut être asymptomatique ou provoquer fatigue, douleurs articulaires, jaunisse."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont associés à l'hépatite C ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fatigue, douleurs abdominales, jaunisse, mais souvent asymptomatique."
}
},
{
"@type": "Question",
"name": "Les symptômes de l'hépatite D sont-ils similaires ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils ressemblent à ceux de l'hépatite B, avec des complications possibles."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une hépatite E ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fièvre, fatigue, nausées, et jaunisse, surtout dans les zones à risque."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'hépatite A ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Vaccination, hygiène alimentaire, et lavage des mains sont essentiels."
}
},
{
"@type": "Question",
"name": "Quelles mesures pour l'hépatite B ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Vaccination, éviter le partage d'aiguilles et rapports protégés."
}
},
{
"@type": "Question",
"name": "L'hépatite C peut-elle être évitée ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter le partage d'aiguilles et pratiquer des rapports protégés aide à prévenir."
}
},
{
"@type": "Question",
"name": "Y a-t-il un vaccin pour l'hépatite E ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccin commercialisé pour l'hépatite E."
}
},
{
"@type": "Question",
"name": "Comment réduire le risque d'hépatite D ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Prévenir l'hépatite B par vaccination réduit le risque d'hépatite D."
}
},
{
"@type": "Question",
"name": "Comment traite-t-on l'hépatite A ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'y a pas de traitement spécifique, repos et hydratation sont recommandés."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour l'hépatite B ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Antiviraux comme la lamivudine ou l'interféron peuvent être prescrits."
}
},
{
"@type": "Question",
"name": "L'hépatite C peut-elle être guérie ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, avec des antiviraux à action directe, la guérison est possible."
}
},
{
"@type": "Question",
"name": "Y a-t-il un vaccin pour l'hépatite B ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un vaccin efficace est disponible pour prévenir l'hépatite B."
}
},
{
"@type": "Question",
"name": "Comment gérer l'hépatite D ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement de l'hépatite B est essentiel, car l'hépatite D dépend de celle-ci."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec l'hépatite B ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Cirrhose, cancer du foie, et insuffisance hépatique sont des complications possibles."
}
},
{
"@type": "Question",
"name": "L'hépatite C peut-elle causer des complications ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut mener à la cirrhose et au cancer du foie sur le long terme."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications de l'hépatite D ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut aggraver l'hépatite B, entraînant des complications hépatiques sévères."
}
},
{
"@type": "Question",
"name": "L'hépatite A entraîne-t-elle des complications ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Rarement, mais des cas graves peuvent survenir, surtout chez les personnes âgées."
}
},
{
"@type": "Question",
"name": "Quelles complications sont liées à l'hépatite E ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Peuvent inclure des cas graves chez les femmes enceintes, comme l'insuffisance hépatique."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour l'hépatite A ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Voyages dans des zones à risque, consommation d'eau contaminée, et aliments crus."
}
},
{
"@type": "Question",
"name": "Quels comportements augmentent le risque d'hépatite B ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Partage d'aiguilles, rapports non protégés, et transfusions sanguines non testées."
}
},
{
"@type": "Question",
"name": "Qui est à risque pour l'hépatite C ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les consommateurs de drogues injectables et les personnes ayant des rapports à risque."
}
},
{
"@type": "Question",
"name": "Les travailleurs de la santé sont-ils à risque d'hépatite ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils sont exposés à des fluides corporels et doivent suivre des protocoles de sécurité."
}
},
{
"@type": "Question",
"name": "Les personnes vivant avec le VIH sont-elles à risque d'hépatite ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles ont un risque accru d'infections par les virus de l'hépatite."
}
}
]
}
]
}
Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran; Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran. Electronic address: fshokri@tums.ac.ir.
The consequences of ineffective communication between patients and clinicians in the ED range from frustration to significant adverse events. Unfortunately, scenarios where we are unable to understand...
Caregivers have significant role in effective treatment and recovery during hospitalization. Communication barriers in health care lead to poor treatment outcome of patients and caregiver's dissatisfa...
A cross-sectional study was conducted among 120 caregivers of psychiatric patients admitted in psychiatric ward of Patan Hospital who were selected by purposive sampling and interviewed using self-dev...
Low extent of communication barrier was perceived by 29.17%, great extent by 25.83%, moderate extent by 24.17% and no barriers were perceived by 20.83% caregivers. There was association between durati...
More than one fourth caregiver's perceived low extent of communication barrier, almost one fourth perceived great extent and less than one fourth perceived moderate extent. There was association betwe...
Language and cultural barriers can affect healthcare outcomes of minority populations. However, limited data are available on communication tools developed to address health disparities resulting from...
This study was conducted at a family health center in a United States urban setting, in the city of Pittsburgh, between November 2019 and August 2020. This study included Japanese adult patients who h...
Sixty Japanese patients met inclusion criteria and completed the survey. More than half of participants found the JECS useful, and those with self-reported limited English proficiency were most likely...
The JECS is a useful communication tool for addressing common barriers faced by Japanese patients seeking care at an American health center where Japanese-speaking physicians work but no clinic staff ...
This letter supplements some ideas put forward by Kim et al., who debated the importance of patient-centered communication as a central notion of patient-centered cancer care in pre- versus post-pande...
Due to various socio-cultural and language related factors, healthcare providers experience barriers when communicating with older culturally and linguistically diverse (CALD) patients with cancer, wh...
In order to lay out the healthcare providers' perceived barriers to communication, the present study identified and compared communication barriers among different healthcare providers when caring for...
An online survey was conducted among healthcare providers in the Netherlands who identified as being involved in the care of CALD patients with cancer (N = 191), specifically; GPs (N...
Overall, low Dutch language proficiency of older CALD patients with cancer, family interpreters providing inadequate translations, not knowing the extent of patients' informational needs, cultural dif...
Migrants and refugees may not access mental health services due to linguistic and cultural discordance between them and health and social care professionals (HSCPs). The aim of this review is to ident...
We undertook a rapid systematic review of the literature (01/01/2011 - 09/03/2022) on seeking and/or providing mental health services in linguistically discordant settings. Quality appraisal was perfo...
58/5,650 papers met the inclusion criteria. Both TCNs (and their carers) and HSCPs experience difficulties when seeking or providing mental health services and language barriers are present. TCNs and ...
Language barriers impede TCNs' access to mental health services. Improving language support options and cultural competency in mental health services is crucial to ensure that individuals from diverse...
Language plays a critical role in health communication, particularly in the management and understanding of non-communicable diseases (NCDs) among elderly populations. This study aimed to explore the ...
This qualitative phenomenological study was conducted with elderly participants aged 60 years and above, all of whom have chronic diseases. In-depth face-to-face interviews were conducted using an int...
Five major themes emerged regarding participants' understanding of NCDs and the perceived language barriers. These include Limited Knowledge and Awareness of NCDs, Misconceptions about NCDs, Mixed per...
The study revealed significant misconceptions about diabetes and hypertension, as well as traditional practices like bloodletting, which were perceived to relieve hypertension symptoms. It also identi...
Family doctors (FDs)/General practitioners (GPs) are the key contact points for young people and their parents regarding Human Papillomavirus (HPV) vaccination. However, their recommendations are infl...
Under the EU4Health project, PROTECT-EUROPE, WONCA Europe led a task to identify and analyse strategies for clinicians' interpersonal communication skills when discussing HPV and its vaccination with ...
Strengths, Weaknesses, Opportunities, Threats (SWOT) analysis using qualitative data focused on HPV vaccine acceptance and communication with the target population. FDs/GPs, members of WONCA Europe, w...
223 FDs/GPs from 36 countries participated. Strengths included face-to-face communication, extensively used to promote the HPV vaccine. Weaknesses involved financial constraints, limited knowledge abo...
It is crucial to train FDs/GPs to address knowledge gaps, enhance communication skills, and maintain a trusting relationship with patients when discussing HPV vaccination. Overcoming financial barrier...
Workers who experience language barriers are at increased risk of work-related injuries and illnesses and face difficulties reporting these health problems to their employer and workers' compensation....
This study merges data from two qualitative studies that investigated experiences with workers' compensation and return-to-work, respectively, for injured workers who experience language barriers. We ...
Almost all workers (34/39) had filed a claim, though most had initially delayed reporting their injuries or illnesses to their employer or to workers' compensation. Workers faced several obstacles to ...
Improving the linguistic and cultural competence of organizations and their representatives is insufficient to address under-reporting among workers who experience language barriers. Efforts to improv...
Understanding disparities in pediatric kidney transplants is important to provide equitable care. We compared transplant outcomes between English-speaking (ES) and interpreter-needing (IN) pediatric k...
Through retrospective review, primary kidney transplant recipients, 0-21 years transplanted between 2005 and 2019, were divided into ES and IN cohorts. Continuous and categorical variables were compar...
Our sample included 211 ES and 37 IN transplant recipients. Compared with the ES, the IN cohort was older at transplant (14.56 vs. 11.03 years; p < 0.01), had more time between kidney failure and tran...
Pediatric kidney transplant recipients requiring interpreter services for healthcare delivery demonstrate fewer post-transplant interactions with their healthcare team (fewer hospitalizations and more...
